Integra LifeSciences Shuffles Leadership to Sharpen Commercial Focus
Event summary
- Mike McBreen appointed executive vice president and chief commercial officer in June 2026.
- Robert T. Davis Jr. named executive vice president for Tissue Reconstruction and Distributed Technologies.
- Christopher Kilburn-Peterson promoted to corporate vice president and president of Tissue Reconstruction division.
- Harvinder Singh takes over as executive vice president and president of Specialty Surgery division.
The big picture
Integra LifeSciences is restructuring its commercial leadership to strengthen market-facing activities, reflecting broader industry trends toward specialized medical technology solutions. The appointments aim to enhance execution capabilities amid increasing competition in neurosurgery and tissue reconstruction markets. With a focus on internal talent development, the company seeks to position experienced leaders at critical business units.
What we're watching
- Execution Risk
- How the new leadership team will accelerate commercial execution and integrate international business under McBreen.
- Strategic Alignment
- Whether the internal talent development focus can sustain long-term growth in competitive medical technology markets.
- Market Impact
- The pace at which these changes translate to improved customer focus and portfolio performance in wound reconstruction and specialty surgery segments.